The effect of care setting in the delivery of high-value colon cancer care

Cancer

Volumn 120, Issue 20, 2014, Pages 3237-3244

  Veenstra, Christine M ^a   Epstein, Andrew J ^b   Liao, Kaijun ^b   Morris, Arden M ^a   Pollack, Craig E ^c   Armstrong, Katrina A ^d  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Academic medical centers; Colon cancer; Cost analysis; Health policy; Incremental cost effectiveness ratio; Survival analysis

Indexed keywords

AGED; ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER RISK; CANCER SPECIFIC SURVIVAL; CANCER STAGING; COHORT ANALYSIS; COLON CANCER; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HEALTH CARE FACILITY; HEALTH CARE QUALITY; HOSPITAL CARE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; OVERALL SURVIVAL; UNIVERSITY HOSPITAL; CANCER REGISTRY; COLONIC NEOPLASMS; ECONOMICS; MEDICARE; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COHORT STUDIES; COLONIC NEOPLASMS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MEDICARE; RETROSPECTIVE STUDIES; SEER PROGRAM; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 84908037017     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28874     Document Type: Article

References (36)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11-30.
2. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2010. Bethesda, MD: National Cancer Institute; 2013.
3. Chia SK, Speers CH, D'yachkova Y, et al. The impact of new chemotherapeutic and hormonal agents on survival in a populationbased cohort of women with metastatic breast cancer. Cancer. 2007; 110:973-979.
4. Loblaw DA, Walker-Dilks C, Winquist E, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review. Clin Oncol (R Coll Radiol). 2013;25:406-430.
5. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harboring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011;12:1004-1012.
6. Seal B, Sullivan S, Ramsey S, et al. Medical costs associated with use of systemic therapy in adults with colorectal cancer. J Manag Care Pharm. 2013;19:461-467.
7. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27: 3677-3683.
8. Temple LK, Hsieh WD, Saltz L, et al. Use of surgery among elderly patients with stage IV colorectal cancer. J Clin Oncol. 2004;22:3475-3484.
9. Mayo SC, Heckman JE, Shore AD, et al. Trends in liver-directed management of patients with colorectal liver metastasis: a population-based analysis. Surgery. 2011;150:204-216.
10. El Zouhairi M, Charabaty A, Pishvaian MJ. Molecularly targeted therapy for metastatic colon cancer: proven treatments and promising new agents. Gastrointest Cancer Res. 2011;4:15-21.
11. Meropol NJ, Schulman KA. The cost of cancer care: issues and implications. J Clin Oncol. 2007;25:180-186.
12. Portner ME. What is value in health care? N Engl J Med. 2010;363: 2477-2481.
13. Meropol NJ, Schrag D, Smith TJ, et al; American Society of Clinical Oncology. American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol. 2009;27:3868-3874.
14. Paulson EC, Mitra N, Sonnad S, et al. National Cancer Institute designation predicts improved outcomes in colorectal cancer surgery. Ann Surg. 2008;248:675-686.
15. Birkmeyer NJ, Goodney PP, Stukel TA, et al. Do cancer centers designated by the National Cancer Institute have better surgical outcomes? Cancer. 2005;103:435-441.
16. Mechanic R, Coleman K, Dobson A. Teaching hospital costs: implications for academic missions in a competitive market. JAMA. 1998; 280:1015-1019.
17. Fox PD, Wasserman J. Academic centers and managed care: uneasy partners. Health Aff (Millwood). 1993;12:85-93.
18. Wennberg JE. Unwarranted variations in healthcare delivery: implications for academic medical centres. BMJ. 2002;325:961-964.
19. Wennberg JE, Thomson PY, Fisher ES, et al. Use of hospitals, physician visits, and hospice care during last 6 months of life among cohorts loyal to highly respected hospitals in the United States. BMJ. 2004;328:607-611.
20. Fisher ES, Wennberg DE, Stukel TA, Gottlieb DJ, Lucas FL, Pinder EL. The implications of regional variations in Medicare spending. Part 2: health outcomes and satisfaction with care. Ann Intern Med. 2003;138:288-298.
21. Ayanian JZ, Weissman JS. Teaching hospitals and quality of care: a review of the literature. Milbank Q. 2002;80:569-593.
22. Bynum JP, Bernal-Delgado E, Gottlieb D, Fisher E. Assigning ambulatory patients and their physicians to hospitals: a method for obtaining population-based provider performance measurements. Health Serv Res. 2007;42:45-62.
23. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36:8-27.
24. Hurwitz HL, Fehrenbacher W, Novotny T, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
25. Jirillo A, Vascon F, Giacobbo M. Bevacizumab in advanced cancer, too much or too little? Ann Oncol. 2008;19:1817-1818.
26. Kemeny NE. Treatment of metastatic colon cancer: "the times they are A-changing." J Clin Oncol. 2013;31:1913-1916.
27. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309-318.
28. McArdle CS, Hole DJ. Influence of volume and specialization on survival following surgery for colorectal cancer. Br J Surg. 2004;91: 610-617.
29. Earle CC, Burstein HJ, Winer EP, Weeks JC. Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol. 2003;21:1447-1451.
30. Ko C, Chaudhry S. The need for a multidisciplinary approach to cancer care. J Surg Res. 2002;105:53-57.
31. Chagpar R, Xing Y, Chiang YJ, et al. Adherence to stage-specific treatment guidelines for patients with colon cancer. J Clin Oncol. 2012;30:972-979.
32. Kahn KL, Adams JL, Weeks JC, et al. Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. JAMA. 2010;303:1037-1045.
33. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291: 2720-2726.
34. Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol. 2003; 21:1383-1389.
35. Kenfield SA, Stampfer MJ, Chan JM, et al. Smoking and prostate cancer survival and recurrence. JAMA. 2011;305:2548-2555.
36. Trock BJ, Han M, Freedland SJ, et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA. 2008;299: 2760-2769.